Trial Profile
A Phase I Dose-Finding Study of E7389 (Halichondrin B Analog) Administered Once Every Three Weeks in Patients With Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Apr 2012
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Acronyms BOLD
- 10 Apr 2012 Actual patient number changed from 35 to 21 as reported by ClinicalTrials.gov.
- 10 Sep 2009 Actual end date (Apr 2005) added as reported by ClinicalTrials.gov.
- 10 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.